As of November 10, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Aptevo Therapeutics Inc. The largest reported stake is Niowave, Inc.'s, at 12.2%. 11 filings are on record since July 8, 2025 (Schedule 13G, June 22, 2026).
Sell to companies like Aptevo Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: CVI Investments, Inc. · Sole voting: 0 · Shared voting: 83,854 · Sole dispositive: 0 · Shared dispositive: 83,854 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Niowave, Inc. · Sole voting: 151,723 · Shared voting: 0 · Sole dispositive: 151,723 · Shared dispositive: 0 · SCHEDULE 13G, 2026-06-22
- · Holder: Point72 Asset Management, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: CVI Investments, Inc. · Percent: 8.2% · SCHEDULE 13G/A
- · Holder: Bank Of America Corp · Percent: 0% · SCHEDULE 13G/A
Aptevo Therapeutics Inc. has 11 Schedule 13D or 13G filings on record since 2025-07-08. 4 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Niowave, Inc. | 12.2% | 151,723 | SCHEDULE 13G, 2026-06-22 | 2026-05-25 |
| Ayrton Capital LLC | 10% | 358,150 | SCHEDULE 13G, 2025-08-13 | 2025-06-30 |
| YA II PN, Ltd. | 9.99% | 357,842 | SCHEDULE 13G, 2025-07-08 | 2025-06-16 |
| CVI Investments, Inc. | 6.3% | 83,854 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| L1 Capital Global Opportunities Master Fund, Ltd. | 4.99% | 164,300 | SCHEDULE 13G/A, 2025-08-14 | 2025-08-14 |
| Point72 Asset Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Bank Of America Corp | 0% | 86 | SCHEDULE 13G/A, 2025-11-07 | 2025-10-31 |
Holding shares or following this stake? See who's behind Aptevo Therapeutics Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Aptevo Therapeutics Inc. and the records around it.
Aptevo Therapeutics Inc. elsewhere on the record
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Who owns it
Companies that share a holder
- YA II PN, Ltd. also filed stake reports on 13 other companies: Ives Ultra AI Opportunities Inc. (Oct 2026), Beneficient (Oct 2026), Optimi Health Corp. (Oct 2026)
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
- L1 Capital Global Opportunities Master Fund, Ltd. also filed stake reports on 42 other companies: Youlife Group Inc. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
Watch Aptevo Therapeutics Inc.
Get an email when Aptevo Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aptevo Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aptevo Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aptevo Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Niowave, Inc. | 151,723 | 0 | 151,723 | 0 | SCHEDULE 13G, 2026-06-22 |
| CVI Investments, Inc. | 0 | 83,854 | 0 | 83,854 | SCHEDULE 13G/A, 2026-08-14 |
| Heights Capital Management, Inc. | 0 | 83,854 | 0 | 83,854 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Aptevo Therapeutics Inc. by CUSIP 03835L702 and gives its principal executive office as 2401 4th Avenue, Suite 1050, Seattle, WA 98121 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-08 | YA II PN, Ltd. | 9.99% | SCHEDULE 13G |
| 2025-08-13 | Ayrton Capital LLC | 10% | SCHEDULE 13G |
| 2025-08-14 | L1 Capital Global Opportunities Master Fund, Ltd. | 4.99% | SCHEDULE 13G/A |
| 2025-08-14 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-09-17 | Point72 Asset Management, L.P. | 9.1% | SCHEDULE 13G |
| 2025-10-06 | Bank Of America Corp | 15% | SCHEDULE 13G |
| 2025-11-07 | Bank Of America Corp | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Point72 Asset Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-02-17 | CVI Investments, Inc. | 8.2% | SCHEDULE 13G/A |
| 2026-06-22 | Niowave, Inc. | 12.2% | SCHEDULE 13G |
| 2026-08-14 | CVI Investments, Inc. | 6.3% | SCHEDULE 13G/A |
Questions about who owns Aptevo Therapeutics Inc.
Who owns Aptevo Therapeutics Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Aptevo Therapeutics Inc.: Niowave, Inc. (12.2%, Schedule 13G, filed 2026-06-22), Ayrton Capital LLC (10%, Schedule 13G, filed 2025-08-13), YA II PN, Ltd. (9.99%, Schedule 13G, filed 2025-07-08) and CVI Investments, Inc. (6.3%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Aptevo Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Aptevo Therapeutics Inc. on this page are Niowave, Inc. (12.2%), Ayrton Capital LLC (10%) and YA II PN, Ltd. (9.99%).
When did Niowave, Inc. buy into Aptevo Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Niowave, Inc. on this page is the Schedule 13G, filed 2026-06-22, reporting 12.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Aptevo Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 26, 2026 | Form D, private offering | $3.47M sold | Form D page | Source |
| April 18, 2025 | Form D, private offering | $2.10M sold | Form D page | Source |
Aptevo Therapeutics Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Aptevo Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.